Mallinckrodt plc, a global specialty pharmaceutical company, announced the presentation of three posters on TERLIVAZ® for injection in patients with hepatorenal syndrome with rapid reduction in kidney function1 at the 2024 European Association for the Study of the Liver Congress taking place in Milan, Italy from June 5-8, 2024.
